PBLS is Parabilis Medicines, Inc. Common Stock (Healthcare) — a non-dividend-paying stock. Trading at $40.11. Market cap: $4.88B.
Stock snapshot
| Price | $40.11 |
| Market cap | $4.88B |
| Sector | Healthcare |
| Exchange | XNAS |
| Pays dividend | No |
About PBLS
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
Related non-dividend companies
Other non-dividend stocks investors research alongside PBLS. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is PBLS's current stock price?
PBLS (Parabilis Medicines, Inc. Common Stock) is currently trading at $40.11.
Does PBLS pay a dividend?
PBLS (Parabilis Medicines, Inc. Common Stock) does not currently pay a regular dividend.
Track PBLS in DiviDrip
Add PBLS to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search PBLS and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-03. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.